IL266738B2 - Antibodies for Domain 2 of Human CD137 and Uses Thereof in Treatment of Cancer - Google Patents

Antibodies for Domain 2 of Human CD137 and Uses Thereof in Treatment of Cancer

Info

Publication number
IL266738B2
IL266738B2 IL266738A IL26673819A IL266738B2 IL 266738 B2 IL266738 B2 IL 266738B2 IL 266738 A IL266738 A IL 266738A IL 26673819 A IL26673819 A IL 26673819A IL 266738 B2 IL266738 B2 IL 266738B2
Authority
IL
Israel
Prior art keywords
antibody
antigen
binding fragment
seq
binding
Prior art date
Application number
IL266738A
Other languages
English (en)
Hebrew (he)
Other versions
IL266738B1 (en
IL266738A (en
Inventor
Peter Ellmark
Sara Fritzell
Christina Furebring
Jessica Petersson
Anna Sall
Karin Enell Smith
Laura Varas
Schantz Laura Von
Niina Veitonmaki
Original Assignee
Alligator Bioscience Ab
Peter Ellmark
Sara Fritzell
Christina Furebring
Jessica Petersson
Anna Sall
Karin Enell Smith
Laura Varas
Schantz Laura Von
Niina Veitonmaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience Ab, Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Schantz Laura Von, Niina Veitonmaki filed Critical Alligator Bioscience Ab
Publication of IL266738A publication Critical patent/IL266738A/en
Publication of IL266738B1 publication Critical patent/IL266738B1/en
Publication of IL266738B2 publication Critical patent/IL266738B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL266738A 2016-11-21 2017-11-21 Antibodies for Domain 2 of Human CD137 and Uses Thereof in Treatment of Cancer IL266738B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1619648.7A GB201619648D0 (en) 2016-11-21 2016-11-21 Novel antibodies and uses thereof
PCT/EP2017/079930 WO2018091740A2 (en) 2016-11-21 2017-11-21 Novel antibodies and uses thereof

Publications (3)

Publication Number Publication Date
IL266738A IL266738A (en) 2019-07-31
IL266738B1 IL266738B1 (en) 2024-02-01
IL266738B2 true IL266738B2 (en) 2024-06-01

Family

ID=57993708

Family Applications (1)

Application Number Title Priority Date Filing Date
IL266738A IL266738B2 (en) 2016-11-21 2017-11-21 Antibodies for Domain 2 of Human CD137 and Uses Thereof in Treatment of Cancer

Country Status (14)

Country Link
US (3) US11535678B2 (enExample)
EP (1) EP3541844A2 (enExample)
JP (1) JP7068303B2 (enExample)
KR (1) KR102679632B1 (enExample)
CN (1) CN109963873B (enExample)
AU (1) AU2017360094B2 (enExample)
BR (1) BR112019010265A2 (enExample)
CA (1) CA3044339A1 (enExample)
GB (1) GB201619648D0 (enExample)
IL (1) IL266738B2 (enExample)
MX (1) MX2019005911A (enExample)
NZ (1) NZ754051A (enExample)
RU (1) RU2019116624A (enExample)
WO (1) WO2018091740A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
US10174122B2 (en) * 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof
BR112019017241A2 (pt) 2017-04-13 2020-04-14 Agenus Inc. anticorpos anti-cd137 e métodos de uso dos mesmos
CR20200042A (es) * 2017-08-01 2020-03-03 Lilly Co Eli Anticuerpos anti-cd137
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
CN112020517B (zh) 2018-03-23 2024-10-29 伊莱利利公司 用于与抗pd-l1抗体组合的抗cd137抗体
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
GB201811408D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
BR112021000394A2 (pt) 2018-07-12 2021-04-06 F-Star Beta Limited Moléculas de anticorpo que se ligam a pd-l1 e cd137
JP7598312B2 (ja) 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
MX2021001431A (es) * 2018-08-10 2021-05-12 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
CN112739718B (zh) * 2018-09-12 2024-11-26 祐和医药科技(北京)有限公司 抗tnfrsf9抗体及其用途
US12227582B2 (en) 2019-01-02 2025-02-18 Qlsf Biotherapeutics Inc. CD137 agonist antibodies and uses thereof
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
BR112021026309A2 (pt) 2019-06-26 2022-06-07 Ap Biosciences Inc Anticorpos para ativação de células t
KR20220087479A (ko) * 2019-11-13 2022-06-24 허페이 한커맵 바이오테크놀로지 컴퍼니 리미티드 인간 4-1bb와 결합할 수 있는 분자 및 이의 응용
MX2022008412A (es) 2020-01-07 2022-08-08 Univ Texas Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer.
KR20220132555A (ko) 2020-01-29 2022-09-30 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nrg1 융합체를 사용한 암 치료를 위한 egfr/her2 티로신 키나제 억제제 및/또는 her2/her3 항체의 사용
KR20220133238A (ko) 2020-01-29 2022-10-04 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Nrg1 융합체가 있는 암의 치료를 위한 포지오티닙의 용도
JP7715722B2 (ja) * 2020-02-28 2025-07-30 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト及びその使用
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
CN113842456B (zh) * 2020-06-28 2022-07-26 上海齐鲁制药研究中心有限公司 一种抗人4-1bb的单克隆抗体制剂及其用途
WO2022002063A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 一种4-1bb结合蛋白及其应用
KR20230129484A (ko) * 2021-01-08 2023-09-08 베이징 한미 파마슈티컬 컴퍼니 리미티드 4-1bb와 특이적으로 결합하는 항체 및 그 항원 결합단편
JP2024522234A (ja) 2021-06-18 2024-06-11 アリゲーター・バイオサイエンス・アーベー 新規な併用療法及びその使用
US20250084155A1 (en) 2021-09-29 2025-03-13 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof
WO2023126821A1 (en) * 2021-12-29 2023-07-06 Curateq Biologics Private Limited C1q binding assay
GB202210965D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
GB202210957D0 (en) 2022-07-27 2022-09-07 Alligator Bioscience Ab Novel dosages
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4789724A2 (en) * 2022-09-22 2026-08-12 ABlink Biotech Co., Ltd. Anti-4-1bb nanobody 137-7, preparation therefor, and use thereof
CN116041517B (zh) * 2022-12-19 2025-02-25 首都医科大学附属北京胸科医院 一种抗人cd137抗体及其应用
CN116162162B (zh) * 2022-12-19 2025-05-27 首都医科大学附属北京胸科医院 一种大鼠抗小鼠cd137抗体或其功能性片段、工具抗体及其应用
CN116271009A (zh) * 2023-01-13 2023-06-23 深圳市乐土生物医药有限公司 含有CpG佐剂和4-1BB抗体的药物组合物及其用途
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016029073A2 (en) * 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2016134358A1 (en) * 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
AR046094A1 (es) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co Anticuerpos completamente humanos contra 4-1bb humano
TWI423814B (zh) 2006-09-01 2014-01-21 Genticel 用於引發特異性細胞毒性ｔ淋巴細胞（ｃｔｌ）反應之組成物，包含一淋巴去除性化合物以及一含有抗原序列且以專業化抗原呈現細胞為標靶之分子
BR112017024770A2 (pt) * 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016029073A2 (en) * 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2016134358A1 (en) * 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOLANOS-MATEO, ELIXABET, ET AL., FOCUSING AND SUSTAINING THE ANTITUMOR CTL EFFECTOR KILLER RESPONSE BY AGONIST ANTI-CD137 MAB., 6 November 2014 (2014-11-06) *
PETERS, SHIRLEY J., ET AL., ENGINEERING AN IMPROVED IGG4 MOLECULE WITH REDUCED DISULFIDE BOND HETEROGENEITY AND INCREASED FAB DOMAIN THERMAL STABILITY., 13 July 2012 (2012-07-13) *
RYAN, JOSEPH M., ET AL., ENHANCING THE SAFETY OF ANTIBODY-BASED IMMUNOMODULATORY CANCER THERAPY WITHOUT COMPROMISING THERAPEUTIC BENEFIT: CAN WE HAVE OUR CAKE AND EAT IT TOO?., 25 February 2016 (2016-02-25) *
SANCHEZ?PAULETE, ALFONSO R., ET AL., DECIPHERING CD137 (4?1BB) SIGNALING IN T?CELL COSTIMULATION FOR TRANSLATION INTO SUCCESSFUL CANCER IMMUNOTHERAPY., 1 March 2016 (2016-03-01) *
SEGAL, NEIL H., ET AL., RESULTS FROM AN INTEGRATED SAFETY ANALYSIS OF URELUMAB, AN AGONIST ANTI-CD137 MONOCLONAL ANTIBODYINTEGRATED SAFETY ANALYSIS OF URELUMAB., 18 October 2016 (2016-10-18) *
VINAY, DASS S., AND BYOUNG S. KWON., THERAPEUTIC POTENTIAL OF ANTI-CD137 (4-1BB) MONOCLONAL ANTIBODIES., 3 March 2016 (2016-03-03) *

Also Published As

Publication number Publication date
US20190352414A1 (en) 2019-11-21
GB201619648D0 (en) 2017-01-04
KR20190086691A (ko) 2019-07-23
CN109963873B (zh) 2023-12-26
US11535678B2 (en) 2022-12-27
AU2017360094B2 (en) 2024-12-12
IL266738B1 (en) 2024-02-01
US12509526B2 (en) 2025-12-30
WO2018091740A2 (en) 2018-05-24
NZ754051A (en) 2023-05-26
RU2019116624A (ru) 2020-12-21
US10689454B2 (en) 2020-06-23
BR112019010265A2 (pt) 2019-09-17
US20190352411A1 (en) 2019-11-21
WO2018091740A3 (en) 2018-06-28
US20230295325A1 (en) 2023-09-21
MX2019005911A (es) 2019-07-08
JP2020501531A (ja) 2020-01-23
AU2017360094A1 (en) 2019-06-20
EP3541844A2 (en) 2019-09-25
KR102679632B1 (ko) 2024-06-28
IL266738A (en) 2019-07-31
JP7068303B2 (ja) 2022-05-16
RU2019116624A3 (enExample) 2021-01-29
CA3044339A1 (en) 2018-05-24
CN109963873A (zh) 2019-07-02

Similar Documents

Publication Publication Date Title
US12509526B2 (en) Anti-CD137 antibodies and uses thereof
US12173082B2 (en) Bispecific polypeptides against CD137
US20190161555A1 (en) Bispecific Antibodies Directed Against OX40 and a Tumor-Associated Antigen
KR20220167342A (ko) 변형된 중쇄 불변 영역을 포함하는 항체
BR112017002342A2 (en) new antibodies and their uses
US20220073635A1 (en) Novel polypeptides
US20220064325A1 (en) Novel polypeptides
AU2024270136A1 (en) Anti-il1rap antibodies
JP2024522234A (ja) 新規な併用療法及びその使用
WO2024023118A1 (en) Novel dosages of anti-cd137 antibody
WO2024023120A1 (en) Novel dosages of anti-cd137 antibody
HK40003232A (en) Novel bispecific polypeptides against cd137
HK40004686B (en) Novel bispecific polypeptides against cd137